Safety and Efficacy of NK510 to Treat Gastric Cancer
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this treatment will be evaluated.
Gastric Cancer
DRUG: NK510|DRUG: Tislelizumabï¼Œatezolizumab or Trastuzumab
Dose-Limiting Toxicity, To evaluate the DLT during N510 treatment, 6 weeks|Maximal Tolerable Dose, To evaluate the MTD of NK510, 6 weeks
Overall response rate (ORR), Effectiveness Metrics, 6 weeks
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this treatment will be evaluated.